Logo
x

Search

Subscribe Now

Glaucoma

Intraocular Drug Delivery: Patrick Mooney from SpyGlass Pharma in Conversation with PharmaShots

Intraocular Drug Delivery: Patrick Mooney from SpyGlass Pharma in Conversation with PharmaShots

  • June 10, 2024
Théa Open Innovation Signs a License Agreement with Galimedix to Develop and Commercialize GAL-101 for Ophthalmic Indications

Théa Open Innovation Signs a License Agreement with Galimedix to Develop and Commercialize GAL-101 for Ophthalmic Indications

  • March 30, 2023
Patrick Mooney, CEO at SpyGlass Pharma, Shares Insights from the 3-Month Data of its Innovative Drug Delivery Platform for Chronic Eye Conditions

Patrick Mooney, CEO at SpyGlass Pharma, Shares Insights from the 3-Month Data of its Innovative Drug Delivery Platform for Chronic...

  • November 29, 2022
AbbVie Collaborated with iSTAR Medical to Develop and Commercialize MINIject Device for Glaucoma

AbbVie Collaborated with iSTAR Medical to Develop and Commercialize MINIject Device for Glaucoma

  • July 20, 2022
Oculis Entered into a License Agreement with Accure Therapeutics to Develop and Commercialize ACT-01 for Acute Optic Neuritis and Glaucoma

Oculis Entered into a License Agreement with Accure Therapeutics to Develop and Commercialize ACT-01 for Acute Optic Neuritis and...

  • March 3, 2022
Aerie Signs an Exclusive Agreement with Santen for Rhopressa and Rocklatan to Treat Glaucoma or Ocular Hypertension in EU and Other Countries

Aerie Signs an Exclusive Agreement with Santen for Rhopressa and Rocklatan to Treat Glaucoma or Ocular Hypertension in EU and Othe...

  • December 7, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.